Unmet need/disease burden

Asthma is the most common chronic respiratory disease worldwide

It is associated with a significant level of illness, disability and preventable deaths

chronic respiratory disease chronic respiratory disease

Treatment recommendations for asthma historically followed a one-size-fits-all, stepwise approach

stepwise approach stepwise approach

A stepwise approach leads to increased time to reach the right treatment plan, since each step up or down takes weeks or, more usually, months to assess whether treatment is effective8

The importance of mild-to-moderate asthma may be underestimated

mild-to-moderate asthma mild-to-moderate asthma

Asthma remains uncontrolled despite effective treatment options

A call to action

Asthma remains uncontrolled Asthma remains uncontrolled

Primary care providers are at the front line of mild-to-moderate asthma care

Primary care providers Primary care providers

Asthma is a heterogeneous disease 18

heterogeneous disease heterogeneous disease

A personalised approach directs treatment to patients most likely to benefit5,18

personalised approach personalised approach
  • This one-size-fits-all approach is based on the assumption that the condition is relatively homogenous and well-defined, and that treatment response is consistent among the population18
  • In reality, however, asthma is a complex and heterogenous disease; the underlying pathophysiology may need further investigation as it may not be linked to symptoms or spirometric measurements18,21
  • The personalised approach applies the principles of personalised medicine to airway diseases. Using personalised medicine to identify key traits in each patient may help to resolve unmet needs and challenges in airways diseases18,21
  • By considering a range of traits using this approach, we can tailor treatment to individual patients and avoid unnecessary therapies22

Footnote

†Patients (n=194) aged from 5 to 50 years who had been seen for asthma in the emergency department and residents of Alberta, Canada.4

‡Patients (n=45) aged from 5 to 50 years who had experienced a near-fatal exacerbation of asthma between 1 August 1994 and 3 March 1996, in Alberta, Canada.4

§Data for n=155 patients, from the National Review of Asthma Deaths in the United Kingdom.5

†According to GINA classification.2
 

Abbreviations

GINA, Global Initiative for Asthma

 

Reference

  1. GBD Chronic Respiratory Disease Collaborators. Lancet Respir Med. 2020;8:585-96;
  2. GBD 2017 Causes of Death Collaborators. Lancet. 2018;392:1736-88;
  3. Asthma UK. 2022. Press release. UK asthma death rates among worst in Europe. https://www.healtheuropa.com/uk-asthma-death-rates-worst/85797. Accessed December 2023;
  4. GBD 2015 Chronic Respiratory Disease Collaborators. Lancet Respir Med. 2017;5:691-706.
  5. Shaw DE et al. Lancet Respir Med. 2021;9:786-94;
  6. GINA. 2023 Report. www.ginasthma.org. Accessed December 2023;
  7. Pavord ID et al. Lancet. 2018;391:350-400.
  8. Thomas A, et al. J Allergy Clin Immunol. 2011;128:915-924.
  9. Bergström SE et al. Respir Med. 2008;102:1335-41;
  10. Dusser D et al. Allergy. 2007;62:591-604;
  11. Mitchell I et al. Chest. 2002;121:1407-13;
  12. Kaplan A. Adv Ther. 2021;38:1369-81;
  13. Soremekun S et al. Thorax. 2023;78:643-52.
  14. Amin S et al. Patient Prefer Adherence. 2020;14:541-51;
  15. Demoly P et al. Eur Respir Rev. 2012;21:66-74;
  16. Price D et al. NPJ Prim Care Respir Med. 2014;24:14009;
  17. Agusti A. Thorax. 2014;69:857-64;
  18. Agusti A et al. Eur Respir J. 2016;47:410-9.
  19. Trevor JL et al. Am J Med. 2018;131:484-91;
  20. Backer V et al. Int J Tuberc Lung Dis. 2007;11:463-9;
  21. McDonald VM et al. Eur Respir J. 2019;53:1802058;
  22. Agustí A et al. Respir Med. 2021;187:106572.
  23. Price D et al. J Asthma Allergy. 2017;10:209-23.
  24. Beasley R et al. Am J Respir Crit Care Med. 2020;201:1480-7

GSK is not responsible for third party links.

NX-KE-ASU-WCNT-240002 | October 2024